Patent · US Active

Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function

US11401337B2 · kind B2 · utility

4Cited by

14References

36Claims

0Family size

Assignee

IGM Biosciences, Inc. · US

Inventors

Ramesh Baliga · Redwood City, US
Dean Ng · San Francisco, US

Key dates

Filing date	Apr 6, 2018
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Jun 4, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/734
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the Cμ3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.